Cresco Labs Inc. (CRLBF)
(Delayed Data from OTC)
$2.05 USD
-0.05 (-2.58%)
Updated May 22, 2024 10:39 AM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
CRLBF 2.05 -0.05(-2.58%)
Will CRLBF be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CRLBF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRLBF
QuidelOrtho (QDEL) Q1 Earnings and Revenues Top Estimates
Will Cresco Labs Inc. (CRLBF) Report Negative Earnings Next Week? What You Should Know
CRLBF: What are Zacks experts saying now?
Zacks Private Portfolio Services
AdaptHealth Corp. (AHCO) Lags Q1 Earnings Estimates
Here's How Cresco Labs (CRLBF) is Placed Before Q1 Earnings
Investors Heavily Search Cresco Labs Inc. (CRLBF): Here is What You Need to Know
Other News for CRLBF
3 Cannabis Stocks That Could Be Millionaire-Makers: May Edition
Analysts Offer Insights on Healthcare Companies: Cresco Labs (OtherCRLBF) and Immunocore Holdings (IMCR)
Cannabis Stocks And ETFs Surged On Marijuana Rescheduling News: WTR's Industry Report Analyzes What's Behind The Optimism
Marijuana rescheduling proposed rule comments due by July 22
Curaleaf Offers Little Upside For Cannabis Investors